An AS model was established in apolipoprotein E knockout(ApoE~(-/-)) mice, which were divided into a normal group, an model group, low/medium/high-dose DZTMW groups, and an atorvastatin positive control group...Its mechanism may involve the regulation of hepatic lipid metabolism by its in vivo active components to ameliorate the "phlegm-turbidity" pathology and reduce liver injury, and the inhibition of systemic inflammation to alleviate the "blood stasis" process. The study can provide a modern biological basis for the theory of "phlegm-stasis intermingling".

14 days ago

Journal

IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • APOE (Apolipoprotein E) • IL1B (Interleukin 1, beta) • CRP (C-reactive protein)

atorvastatin

14d

Mechanisms of Tanyu Tongzhi Optimization Decoction against hyperlipidemia based on transcriptomics and proteomics (PubMed, Zhongguo Zhong Yao Za Zhi)

The rats were randomly assigned to the following groups: model group, atorvastatin calcium group(4.8 mg·kg~(-1)), low-, medium-, and high-dose Tanyu Tongzhi Optimization Decoction(TYTZD) groups(3.6, 7.2, and 14.4 g·kg~(-1)), and a normal diet control group...Western blot indicated that TYTZD reduced TLR4, p-NF-κB, and IL-1β protein expression in liver tissue. In conclusion, TYTZD may exert anti-hyperlipidemic effects through regulation of core targets such as ITGAM, TLR4, and APOC2, and by modulating the TLR4/NF-κB signaling pathway to intervene in inflammatory responses and cholesterol metabolism, thereby achieving multi-target, multi-pathway therapeutic effects against hyperlipidemia.

14 days ago

Journal • IO biomarker

TNFA (Tumor Necrosis Factor-Alpha) • ITGAM (Integrin, alpha M) • TLR4 (Toll Like Receptor 4) • MMP9 (Matrix metallopeptidase 9) • APOE (Apolipoprotein E) • IL1B (Interleukin 1, beta) • TLR2 (Toll Like Receptor 2)

atorvastatin

14d

Mechanistic study of Maiguan Fukang Tablets against atherosclerosis based on UHPLC-QE-MS, network pharmacology, and animal experiments (PubMed, Zhongguo Zhong Yao Za Zhi)

An atherosclerosis(AS) model was established in ApoE~(-/-) mice by feeding a high-fat diet for 14 weeks, and mice were randomly divided into a model group, MGFK high-dose group, MGFK low-dose group, and atorvastatin group...Furthermore, MGFK decreased the apoptosis rate within plaques, upregulated B-cell lymphoma-2(BCL-2) expression, downregulated BCL-2-associated X protein(BAX) and cleaved caspase-3, and promoted the phosphorylation of PI3K and AKT. These findings suggest that MGFK exerts anti-atherosclerotic effects potentially by regulating the PI3K/AKT signaling pathway, thereby reducing apoptosis within plaques, lowering levels of inflammatory cytokines and blood lipids, and attenuating plaque size, lipid content, and foam cell formation.

14 days ago

Journal • IO biomarker

AKT1 (V-akt murine thymoma viral oncogene homolog 1) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • APOE (Apolipoprotein E)

atorvastatin

16d

SABS: Statins Against Bushfire Smoke (clinicaltrials.gov)

P4, N=100, Not yet recruiting, Menzies Institute for Medical Research

16 days ago

New P4 trial

atorvastatin

19d

The TRIB1-PPARγ Axis Regulates Cholesterol Metabolism in Pancreatic Ductal Adenocarcinoma. (PubMed, Ann N Y Acad Sci)

Furthermore, in vivo experiments indicate that PDAC tumors with high TRIB1 expression were more sensitive to the HMGCR inhibitor atorvastatin. Collectively, our findings highlight the critical role of the TRIB1-PPARγ-HMGCR axis in the metabolic rewiring of PDAC and suggest that TRIB1 may serve as a predictive biomarker for optimizing statin-based metabolic therapies.

19 days ago

Journal

PPARG (Peroxisome Proliferator Activated Receptor Gamma) • TRIB1 (Tribbles Pseudokinase 1)

atorvastatin

19d

Integrated transcriptomics and molecular docking identify hub genes and statin regulators in Helicobacter pylori-associated gastric mucosal pathogenesis. (PubMed, Front Cell Infect Microbiol)

To explore potential therapeutic interventions, we performed small-molecule drug prediction and molecular docking for hub genes revealed: Simvastatin: Linked to CCL20, NFKBIA, and ICAM1. Atorvastatin: Associated with CDKN1A, ICAM1, and TNF. TPCA-1: Targeting JAK1. These findings provide a theoretical foundation for further investigation into the molecular mechanisms underlying H. pylori-related diseases.

19 days ago

Journal

BRCA1 (Breast cancer 1, early onset) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • BIRC3 (Baculoviral IAP repeat containing 3) • JAK1 (Janus Kinase 1) • TNFAIP3 (TNF Alpha Induced Protein 3) • CCL20 (C-C Motif Chemokine Ligand 20) • ICAM1 (Intercellular adhesion molecule 1) • IRF1 (Interferon Regulatory Factor 1) • ITGAM (Integrin, alpha M) • SPI1 (Spi-1 Proto-Oncogene) • ETS1 (ETS Proto-Oncogene 1) • IL17A (Interleukin 17A) • STAT1 (Signal Transducer And Activator Of Transcription 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • NFKB2 (Nuclear Factor Kappa B Subunit 2) • NFKBIA (NFKB Inhibitor Alpha 2) • NFKBIE (NFKB Inhibitor Epsilon) • TRAF1 (TNF Receptor Associated Factor 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • E2F1 (E2F transcription factor 1) • EGR1 (Early Growth Response 1) • HSF1 (Heat Shock Transcription Factor 1) • JUNB (JunB Proto-Oncogene AP-1 Transcription Factor Subunit)

simvastatin • atorvastatin

29d

Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis (clinicaltrials.gov)

P2, N=50, Recruiting, CAMC Health System | Not yet recruiting --> Recruiting | Trial completion date: Jun 2026 --> Mar 2027 | Trial primary completion date: Jun 2026 --> Mar 2027

29 days ago

Enrollment open • Trial completion date • Trial primary completion date

atorvastatin

29d

A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries (clinicaltrials.gov)

P=N/A, N=40, Recruiting, Takeda | Not yet recruiting --> Recruiting

29 days ago

Enrollment open • Real-world evidence

atorvastatin